









Pipeline from Collaborations

^ BiTE, ^^ HLE BiTE, † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non Sq NSCLC, †† ZW25, * Assembly is conducting Phase 2 triple combination studies with VBR and a Phase 1 study of ABI-H3733, 1 By MapKure, a JV with SpringWorks

	Molecule/Asset	Indications	Phase	Commerical Rights
	Sotorasib (KRAS G12C)	Solid tumors, CRC, NSCLC	Phase 3	China
	tarlatamab^^ (DLL3)	SCLC	Phase 2	China
	AMG 176 (Mcl-1, SM)	Hematologic malignancies	Phase 1	China
	AMG 427^^ (FLT3)	AML	Phase 1	China
	AMG 509^ (STEAP1 XmAb)	Prostate cancer	Phase 1	China
	AMG 199^^ (MUC17)	GC/GEJC	Phase 1	China
	AMG 650 (oral small molecule)	Solid tumors	Phase 1	China
	AMG 256 (Anti-PD-1 x IL21 mutein)	Solid tumors	Phase 1	China
	Sitravatinib† (multi-kinase inhibitor) + Tislelizumab	NSCLC	Phase 3	Asia ex-Japan, Australia, New Zealand
	Sitravatinib† (monotherapy) + Tislelizumab	HCC, GC/GEJC	Phase 2	Asia ex-Japan, Australia, New Zealand
	Sitravatinib† (monotherapy) + Tislelizumab	Solid tumors	Phase 1	Asia ex-Japan, Australia, New Zealand
	Zanidatamab†† (HER2, bispecific antibody) + Chemotherapy + Tislelizumab	GEA	Phase 3	Asia ex-Japan, Australia, New Zealand
	Zanidatamab†† (monotherapy)	BTC	Phase 2	Asia ex-Japan, Australia, New Zealand
	Zanidatamab†† + Chemotherapy +/- Tislelizumab	BC, GC, GEA	Phase 2	Asia ex-Japan, Australia, New Zealand
	ZW49 (HER2, bispecific ADC)	HER2 expressing cancers	Phase 1	Asia ex-Japan, Australia, New Zealand
	BGB-3245 ¹ (BRAF)	Solid tumors	Phase 1	Asia ex-Japan
	SEA-CD70 (anti-CD70)	MDS, AML	Phase 1	Asia ex-Japan, Australia, New Zealand
	DKN-01(DKK1) + Tislelizumab ± Chemotherapy	GC/GEJC	Phase 2	Option for Asia ex-Japan, Australia, New Zealand
	LBL-007 (anti-LAG-3) + Tislelizumab	Advanced solid tumors	Phase 2	Ex-China
	Vebicorvir (ABI-H0731) (HBV core inhibitor)*	Chronic hepatitis B virus	Phase 2	China
	ABI-H3733 (HBV core inhibitor)	Chronic hepatitis B virus	Phase 1	China